Nanotechnology-based strategies for treatment of ocular disease

被引:239
作者
Weng, Yuhua [1 ,2 ,3 ]
Liu, Juan [2 ,3 ]
Jin, Shubin [2 ,3 ]
Guo, Weisheng [2 ,3 ]
Liang, Xingjie [2 ,3 ]
Hua, Zhongbo [1 ]
机构
[1] Univ Chinese Acad Sci, Coll Mat Sci & Optoelect, Beijing 100049, Peoples R China
[2] Chinese Acad Sci, Ctr Excellence Nanosci, Lab Controllable Nanopharm, Beijing 100190, Peoples R China
[3] Natl Ctr Nanosci & Technol China, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China
关键词
Nanosystems; Nanocarrier; Eye; Ocular disease; Ocular drug delivery; Therapy; Diagnosis; GANCICLOVIR OPHTHALMIC GEL; LOADED BIODEGRADABLE NANOPARTICLES; PIGMENT EPITHELIAL-CELLS; DRUG-DELIVERY; CORNEAL; RETINOBLASTOMA; SAFETY; 0.15-PERCENT; PENETRATION; EXPRESSION;
D O I
10.1016/j.apsb.2016.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ocular diseases include various anterior and posterior segment diseases. Due to the unique anatomy and physiology of the eye, efficient ocular drug delivery is a great challenge to researchers and pharmacologists. Although there are conventional noninvasive and invasive treatments, such as eye drops, injections and implants, the current treatments either suffer from low bioavailability or severe adverse ocular effects. Alternatively, the emerging nanoscience and nanotechnology are playing an important role in the development of novel strategies for ocular disease therapy. Various active molecules have been designed to associate with nanocarriers to overcome ocular barriers and intimately interact with specific ocular tissues. In this review, we highlight the recent attempts of nanotechnology-based systems for imaging and treating ocular diseases, such as corneal diseases, glaucoma, retina diseases, and choroid diseases. Although additional work remains, the progress described herein may pave the way to new, highly effective and important ocular nanomedicines. (C) 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
引用
收藏
页码:281 / 291
页数:11
相关论文
共 101 条
[1]  
Ahmed I., 2003, DRUGS PHARM SCI, V130, P335, DOI [10.1201/9780203912072.ch11, DOI 10.1201/9780203912072.CH11]
[2]   Nanocrystal targeting in vivo [J].
Åkerman, ME ;
Chan, WCW ;
Laakkonen, P ;
Bhatia, SN ;
Ruoslahti, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) :12617-12621
[3]   Proliferation and Migration of Peripheral Retinal Pigment Epithelial Cells Are Associated with the Upregulation of Wingless-Related Integration and Bone Morphogenetic Protein Signaling in Dark Agouti Rats [J].
Al-Hussaini, Heba ;
Kilarkaje, Narayana ;
Shahabi, Golnaz ;
Al-Mulla, Fahad .
MEDICAL PRINCIPLES AND PRACTICE, 2016, 25 (05) :408-416
[4]   Ocular Delivery of Flurbiprofen Based on Eudragit® E-Flurbiprofen Complex Dispersed in Aqueous Solution: Preparation, Characterization, In Vitro Corneal Penetration, and Ocular Irritation [J].
Alejandra Quinteros, Daniela ;
Ignacio Tartara, Luis ;
Daniel Palma, Santiago ;
Hilario Manzo, Ruben ;
Alberto Allemandi, Daniel .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (12) :3859-3868
[5]  
Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
[6]   Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration [J].
Amrite, AC ;
Kompella, UB .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (12) :1555-1563
[7]  
Amrite AC, 2008, MOL VIS, V14, P150
[8]  
Anderson SA, 2000, MAGNET RESON MED, V44, P433, DOI 10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO
[9]  
2-9
[10]  
[Anonymous], 2016, Asian J. Pharm. Sci., DOI [10.1016/j.ajps.2015.11.036, DOI 10.1016/J.AJPS.2015.11.036]